Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NNVC – NanoViricides Inc

NanoViricides, Inc.
NNVC
$1.28
Name : NanoViricides, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $27,607,590.00
EPSttm : -0.5
finviz dynamic chart for NNVC
NanoViricides, Inc.
$1.28
1.54%
$0.02

Float Short %

2.06

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

0.02

EPS Last/This Y

0.28

EPS This/Next Y

Price

1.29

Target Price

6.5

Analyst Recom

1

Performance Q

-11.72

Relative Volume

0.88

Beta

1.32

Ticker: NNVC




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-08NNVC1.420.080.004105
2025-12-09NNVC1.3550.080.004150
2025-12-10NNVC1.320.080.504294
2025-12-11NNVC1.290.080.004312
2025-12-12NNVC1.260.080.004386
2025-12-15NNVC1.2350.070.104661
2025-12-16NNVC1.280.070.004673
2025-12-17NNVC1.250.070.004715
2025-12-18NNVC1.2150.073.004740
2025-12-19NNVC1.250.020.004536
2025-12-22NNVC1.250.030.003347
2025-12-23NNVC1.2050.030.003490
2025-12-26NNVC1.170.030.003557
2025-12-29NNVC1.130.030.003558
2025-12-30NNVC1.1050.030.003584
2025-12-31NNVC1.1150.030.003588
2026-01-02NNVC1.220.030.003587
2026-01-05NNVC1.290.030.003617
2026-01-06NNVC1.290.020.004551
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-08NNVC1.43- - -0.56
2025-12-09NNVC1.37- - -0.56
2025-12-10NNVC1.33- - -0.56
2025-12-11NNVC1.29- - -0.56
2025-12-12NNVC1.25- - -0.56
2025-12-15NNVC1.23- - -0.56
2025-12-16NNVC1.23- - -0.56
2025-12-17NNVC1.25- - -0.56
2025-12-18NNVC1.22- - -0.56
2025-12-19NNVC1.25- - -0.35
2025-12-22NNVC1.27- - -0.35
2025-12-23NNVC1.21- - -0.35
2025-12-26NNVC1.17- - -0.35
2025-12-29NNVC1.12- - -0.35
2025-12-30NNVC1.10- - -0.35
2025-12-31NNVC1.12- - -0.35
2026-01-02NNVC1.22- - -0.35
2026-01-05NNVC1.28- - -0.35
2026-01-06NNVC1.29- - -0.35
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-08NNVC0.0001.31
2025-12-09NNVC0.0001.31
2025-12-10NNVC0.0001.02
2025-12-11NNVC0.0001.02
2025-12-12NNVC0.0001.02
2025-12-15NNVC0.0001.02
2025-12-16NNVC0.0001.02
2025-12-17NNVC0.0001.02
2025-12-18NNVC0.0001.02
2025-12-19NNVC0.0000
2025-12-22NNVC0.000.570.85
2025-12-23NNVC0.000.570.85
2025-12-26NNVC0.000.572.06
2025-12-29NNVC0.000.572.06
2025-12-30NNVC0.000.572.06
2025-12-31NNVC0.000.572.06
2026-01-02NNVC0.000.572.06
2026-01-05NNVC0.000.482.06
2026-01-06NNVC0.000.482.06
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.1

Avg. EPS Est. Current Quarter

-0.08

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

Institutional Transactions

0.48

Beta

1.32

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

7

Growth Score

18

Sentiment Score

95

Actual DrawDown %

85.2

Max Drawdown 5-Year %

-85.1

Target Price

6.5

P/E

Forward P/E

PEG

P/S

P/B

3.13

P/Free Cash Flow

EPS

-0.51

Average EPS Est. Cur. Y​

-0.35

EPS Next Y. (Est.)

-0.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.88

Return on Equity vs Sector %

-140.3

Return on Equity vs Industry %

-125.2

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.35

EBIT Estimation

NanoViricides, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 7
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
stock quote shares NNVC – NanoViricides Inc Stock Price stock today
news today NNVC – NanoViricides Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NNVC – NanoViricides Inc yahoo finance google finance
stock history NNVC – NanoViricides Inc invest stock market
stock prices NNVC premarket after hours
ticker NNVC fair value insiders trading